• linkedin
  • Increase Font
  • Sharebar

    Aflibercept shows macular perfusion gains in VISTA subanalysis


    Majority had nonperfusion

    When analyzing all 4 quadrants, 60% to 70% had nonperfusion, or ischemia, as graded by the reading center. In the group receiving laser treatment, 15% or less had improvement, compared with 45% and 40% in the aflibercept groups.

    “On the flip side, regarding the proportion of patients with worsening perfusion status at week 100, 25% had worsening [in the laser group] compared to 9% in the aflibercept groups,” Dr. Dhoot said. “There were significantly improved results with aflibercept.”

    When focusing on the quadrant that encompassed the macula and asking how baseline macular ischemia fared with visual acuity and anatomic outcomes, 66% to 75% of patients had baseline ischemia. Patients with baseline ischemia had severe disease as marked by worse vision by about 5 letters and increased central retinal thickness.

    “The baseline distribution of the diabetic retinopathy severity score also was worse in patients with baseline ischemia,” Dr. Dhoot added.

    When patients in the subanalysis had reperfusion or changes in their status, the proportion with improvement was about 50%.

    “In terms of visual acuity, patients had a similar visual acuity whether or not they had ischemia improvement,” he said.

    Dilsher S. Dhoot, MD

    p. 805-963-1648

    e. [email protected].

    This article was adapted from a presentation that Dr. Dhoot delivered at the 2017 American Academy of Ophthalmology meeting. Dr. Dhoot is a consultant for Alimera Sciences, Allergan, Genentech, Notal Vision, Regeneron, and Santen.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow

    var script= ' ';